StockNews.com began coverage on shares of Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) in a note issued to investors on Tuesday. The firm set a "hold" rating on the biotechnology company's stock.
Separately, Northland Securities downgraded shares of Nabriva Therapeutics from an "outperform" rating to an "underperform" rating in a report on Friday, January 6th.
Get Nabriva Therapeutics alerts:Nabriva Therapeutics Stock Up 5.7 %
NASDAQ:NBRV opened at $1.49 on Tuesday. The firm has a market cap of $45.65 million, a P/E ratio of -0.08 and a beta of 1.67. The company has a debt-to-equity ratio of 0.02, a quick ratio of 1.40 and a current ratio of 2.20. Nabriva Therapeutics has a fifty-two week low of $1.22 and a fifty-two week high of $14.19. The firm has a 50-day simple moving average of $1.97 and a two-hundred day simple moving average of $3.74.
Nabriva Therapeutics (NASDAQ:NBRV – Get Rating) last released its quarterly earnings data on Thursday, November 10th. The biotechnology company reported ($4.21) earnings per share for the quarter, missing analysts' consensus estimates of ($4.03) by ($0.18). The firm had revenue of $9.15 million for the quarter, compared to the consensus estimate of $10.68 million. Nabriva Therapeutics had a negative net margin of 133.25% and a negative return on equity of 120.02%. Analysts predict that Nabriva Therapeutics will post -17.37 earnings per share for the current fiscal year.Hedge Funds Weigh In On Nabriva Therapeutics
An institutional investor recently raised its position in Nabriva Therapeutics stock. Renaissance Technologies LLC increased its holdings in Nabriva Therapeutics plc (NASDAQ:NBRV – Get Rating) by 102.1% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 795,938 shares of the biotechnology company's stock after buying an additional 402,144 shares during the quarter. Renaissance Technologies LLC owned 0.13% of Nabriva Therapeutics worth $145,000 at the end of the most recent reporting period. 0.23% of the stock is currently owned by institutional investors and hedge funds.
Nabriva Therapeutics Company Profile
(Get Rating)
Nabriva Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and commercialization of novel anti-infective agents to treat serious infections. Its product pipeline includes Lefamulin, CONTEPO, and BC-7013. The company was founded in October 2005 and is headquartered in Dublin, Ireland.
Further Reading
- Get a free copy of the StockNews.com research report on Nabriva Therapeutics (NBRV)
- Don't Miss These 2 Mid-Cap Techs That Broke Out Last Week
- Is Macau a Sinking Ship for Wynn Resorts?
- Why Warner Bros Discovery Is the S&P's Hottest Stock
- Pinterest is the Social Commerce Platform to Watch in 2023
- Is Walgreens Boots Alliance Earnings Miss Good For Investors?
Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.